Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
Vietnam Investment Review on MSN
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...
This article is based on a poster originally authored by Peter Hsueh, Lili Qin, Jane Liu and Wenlin Ren. Target proteins are central to the antibody discovery process. These reagents play a critical ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from I to I (R) (Idea to IND), ranging from target validation and ...
Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Vin Singh Founder and Chief Executive Officer BullFrog AI Holdings, Inc.
Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...
Valink Therapeutics ("Valink"), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback